Quality, non-clinical and clinical issues relating specifically to recombinant adeno-associated viral vectors

Current effective version

PDF icon<b>Revision 1 - Reflection paper</b>

Reference numberCHMP/GTWP/587488/2007 Rev. 1
KeywordsAdeno-associated virus, self complementary adeno-associated virus, recombinant adeno-associated virus, production systems, quality, non-clinical, clinical, follow-up, tissue tropism, germ-line transmission, environmental risk, immunogenicity, biodistribution, shedding, animal models, persistence, reactivation, advanced therapy medicinal products (ATMPs), gene therapy medicinal products
DescriptionThis document aims to discuss quality, non-clinical and clinical issues that should be considered during the development of medicinal products derived from adeno-associated viral vectors. It indicates requirements that might be expected at the time of a marketing authorisation application.

Document history

Revision 1

Current version

PDF iconReflection paper

PDF iconOverview of comments

PDF iconConcept paper

Published: 08/07/2010

Published: 08/07/2010

Published: 19/03/2009

Related content

How useful was this page?

Add your rating